Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03058939
Recruitment Status : Withdrawn (Study never activated to enrollment.)
First Posted : February 23, 2017
Last Update Posted : September 3, 2018
Sponsor:
Information provided by (Responsible Party):
University of Chicago

Brief Summary:
This is a two-stage phase II study with a single arm design. It will be conducted in women with breast cancer with stages IIA to IIIC (defined by AJCC 2009 classification) of all histological subtypes. All patients will receive 16 doses of paclitaxel; three breast ultrasound tests and tumor pathologic response evaluation will be used to assess the response to treatment.

Condition or disease Intervention/treatment Phase
Breast Cancer Breast Cancer Stage II Breast Cancer Stage III Drug: Paclitaxel Drug: Perjeta Drug: Herceptin SC Drug: Tamoxifen Drug: Letrozole Drug: LHRH agonist Drug: FEC Drug: Carboplatin Phase 2

Detailed Description:

Each patient will be assigned one of the following groups: 1) complete response, 2) partial response, 3) stable disease, 4) progressive disease, 5) early death from malignant disease, 6) early death from toxicity, 7) early death because of other cause, or 8) unknown (not assessable, insufficient data). Patients with a good response to 8 doses of paclitaxel (complete response or partial response that are operable) will receive an additional 8 courses of paclitaxel chemotherapy before surgery and radiotherapy. The overall response for these patients will be assessed by ultrasonography after a total of 16 weeks of Taxol therapy. Patients with poor response (defined as stable disease or progressive disease or partial response inoperable) as best response after eight weekly courses of paclitaxel will receive 8 cycles of weekly PC. The overall response for these patients will also be assessed by ultrasonography after 8 courses of PC therapy. Patients with poor response to 8 courses of paclitaxel followed by 8 courses of PC based on ultrasound assessment will be regarded as failing to respond to treatment. These patients will receive 4 cycles of 3-weekly FEC and will be followed up. Patients in response groups 4-8 above will be considered as failing to respond to treatment.

All conclusions will be based on all eligible patients. The schema for the study is presented in Figures 4-1, 4-2 and 4-3. Patients with a global deterioration of health status requiring discontinuation of treatment without objective evidence of disease progression at that time will be classified as having "symptomatic deterioration". Every effort will be made to document the objective progression even after discontinuation of treatment. All Premenopausal patients will receive LHRH agonist for two years for contraception and fertility preservation. Hormone-receptor positive patients will receive hormonal therapy with tamoxifen or letrozole after surgery, radiotherapy and LHRH agonist according to the expression of hormone receptors ER and PgR (see glossary and section 10.3) and according to the state of primary menopause (see glossary) at the onset of the study. Patients with HER2-positive disease (see glossary and section 10.3) will receive 5 threeweekly courses of trastuzumab (Herceptin SC) with pertuzumab (Perjeta). After that pts will continue receiving trastuzumab to complete total of 18 doses within 1 year of treatment.

The study is designed to estimate the RR of breast cancer patients to weekly paclitaxel chemotherapy and to determine the RR to weekly PC combination chemotherapy in patients resistant to or with poor response (including early progression) while on weekly single agent paclitaxel.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Assessing the REsponse Rate of Weekly Neo-adjuvanT pacliTAxel (Taxol) in Nigerian Women With Breast Cancer (ARETTA)
Estimated Study Start Date : November 2018
Estimated Primary Completion Date : April 2019
Estimated Study Completion Date : June 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
Drug Information available for: Paclitaxel

Arm Intervention/treatment
Experimental: Paclitaxel
Investigators plan to treat patients with paclitaxel weekly for a total of approximately 16 weeks (8 weeks before ultrasonography for response assessment and 8 weeks before surgery in good responders). Paclitaxel 80mg/m2 will be given on days 1, 8, 15 and so on for a total of 8 doses.
Drug: Paclitaxel
Administered to all patients for a minimum of 8 doses with a possible maximum of 16 doses.
Other Name: Taxol

Carboplatin
After first 8 weeks of paclitaxel, those with progressive disease (based on breast US assessment) or partial response but inoperable will have carboplatin added to their regimen. Patients will receive 8 cycles of weekly paclitaxel and carboplatin (PC).
Drug: Carboplatin
Only administered to patients who receive paclitaxel and were assessed as having poor response (defined as stable disease or progressive disease or partial response inoperable).

Fluorouracil Epirubicin Hydrochloride Cyclophonsphamide (FEC)
Patients with poor response to 8 courses of paclitaxel followed by 8 courses of PC based on ultrasound assessment will be regarded as failing to respond to treatment. These patients will receive 4 cycles of 3-weekly FEC and will be followed up.
Drug: FEC
Only administered to patients who received paclitaxel and carboplatin, and were assessed as having poor response (defined as stable disease or progressive disease or partial response inoperable).

LHRH (luteinizing hormone-releasing hormone)
All Premenopausal patients will receive LHRH agonist for two years for contraception and fertility preservation.
Drug: LHRH agonist
Administered to all premenopausal patients.

Tamoxifen or letrozole
Hormone-receptor positive patients will receive hormonal therapy with tamoxifen or letrozole after surgery, radiotherapy and LHRH agonist according to the expression of hormone receptors and according to the state of primary menopause at the onset of the study.
Drug: Tamoxifen
Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.

Drug: Letrozole
Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.

Herceptin SC and Perjeta
Patients with HER2-positive disease (see glossary and section 10.3) will receive 5 three-weekly courses of trastuzumab (Herceptin SC) with pertuzumab (Perjeta). After that pts will continue receiving trastuzumab to complete total of 18 doses within 1 year of treatment.
Drug: Perjeta
Only administered to patients with HER2-positive disease.
Other Name: Pertuzumab

Drug: Herceptin SC
Only administered to patients with HER2-positive disease.
Other Name: Trastuzumab




Primary Outcome Measures :
  1. Measure overall clinical response rate (OCR) [ Time Frame: 24 months ]
    OCR will be calculated as the proportion of patients with an overall response of complete clinical response (CCR) or partial clinical response (PCR), where tumor response is based on change in tumor diameter after treatment.

  2. Measure of complete pathologic response (pCR) [ Time Frame: 24 months ]
    The absence of residual invasive disease in the breast and in the axillary lymph nodes at the completion of treatment will be measured.


Secondary Outcome Measures :
  1. Number of participants with adverse events [ Time Frame: 24 months ]
    Incidence and severity of adverse drug reactions (AE) and serious adverse drug reactions (SAE) including clinical laboratory values, vital signs, ECGs and dose interruptions.

  2. Time until progression free survival (PFS) [ Time Frame: From start date of therapy to the date of first documented disease progression or death from any cause, whichever may come first, assessed up to 100 months ]
  3. Duration of response (DOR) [ Time Frame: From first reponse to the date of first documented disease progression, assessed up to 24 months ]
  4. Analysis of changes from baseline using the quality of life (QoL) instrument [ Time Frame: From start date of therapy to the date of first documented disease progression or death from any cause, whichever may come first, assessed up to 100 months. ]
    The various domains of QoL over time and the changes from baseline using the validated (by the European Organization for Research and Treatment of Cancer (EORTC)) QoL instrument (global and breast module).

  5. To assess the genetic and epigenetic factors associated with breast cancer in Nigeria [ Time Frame: From start date of therapy to the date of death from any cause, assessed up to 100 months ]
    Through correlative study of molecular markers and tumor subtypes/tumor biology with patient's characteristics, response to treatment and patients' outcome

  6. Blood concentrations of Perjeta before each dose of Perjeta/Herceptin/paclitaxel/PC [ Time Frame: 24 months ]
    To determine the profile of Perjeta given in combination with Herceptin SC, paclitaxel and paclitaxel + carboplatinum

  7. Blood concentrations of Herceptin SC before each dose of Herceptin/paclitaxel/PC [ Time Frame: 24 months ]
    To determine the profile of Herceptin SC given in combination with Perjeta, paclitaxel and PC

  8. Analysis of hormone recepters (ER and PgR) and HER2 [ Time Frame: Through study completion an average of two years ]
    To determine the pattern of response to weekly paclitaxel and PC in combination with hormone therapy or with H/Ptz dual anti-HER2 blockade based on status of clinical markers ! Hormone receptors (ER and PgR) and HER2, and other markers.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Women ages of 18 to 70 years old.
  2. Biopsy-accessible breast tumor of significant size for core needle biopsy (≥ 2cm).
  3. Patients with histologically confirmed carcinoma of the female breast with any or unknown HRs/HER2 status
  4. Clinical stages IIA -IIIC. (AJCC 2009) (Appendix A)
  5. Chemotherapy-naïve patients (for this malignancy)
  6. Performance status: ECOG performance status 0−3 (Appendix B)
  7. Non-pregnant and not nursing. Women of childbearing potential must take the pregnancy test and must commit to receive LHRH agonist Zoladex (goserelin) for two years starting from the commencement of the study medications.
  8. Required Initial Laboratory Data. Adequate hematologic, renal and hepatic function, as defined by each of the following:

    1. Granulocyte ≥ 1,500/μL
    2. Platelet count ≥ 100,000/μL
    3. Absolute neutrophil count (ANC) ≥ l500/μL
    4. Hemoglobin³10g/dL
    5. Bilirubin ≤ 1.5 x upper limit of normal
    6. SGOT and SGPT < 2.5 x upper limit of normal for patients without liver metastases
    7. Creatinine within institutional normal limits or glomerular filtration rate ≥ 30 mL/min/1.73 m2 by CKD EPI equation (see http://mdrd.com/ for calculator)

Exclusion Criteria:

  1. Pregnant or lactating women. Women of childbearing potential not using a reliable and appropriate contraceptive method. Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential.

    Patients will agree to continue the use of acceptable form of contraception for 30 days from the date of last drug administration.

  2. Patients with brain metastasis.
  3. Serious, uncontrolled, concurrent infection(s).
  4. Patients who have received more than 4 weeks of tamoxifen therapy for this malignancy. Patient who have received tamoxifen or raloxifene for purposes of chemoprevention (e.g. Breast Cancer Prevention Trial or for other past indications (including previous breast cancer) are eligible. Tamoxifen or raloxifene therapy will be discontinued at least one month before the patient is enrolled on this study.
  5. Treatment for other carcinomas within the last 5 years, except non-melanoma skin cancer and treated cervical carcinoma in-situ (CCIS).
  6. Participation in any investigational drug study within 4 weeks preceding the start of study treatment.
  7. Other serious uncontrolled medical conditions that the investigator feels might compromise study participation including but not limited to chronic or active infection, HIV-positive patient, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled Diabetes mellitus, or psychiatric illness/social situations that would limit compliance with study requirements.
  8. Unwillingness to participate or inability to comply with the protocol for the duration of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03058939


Locations
Layout table for location information
Nigeria
Lagos State University College of Medicine
Ikeja, Lagos State, Nigeria
Sponsors and Collaborators
University of Chicago
Investigators
Layout table for investigator information
Principal Investigator: Olufunmilayo I. Olopade, MD University of Chicago Center for Global Health

Layout table for additonal information
Responsible Party: University of Chicago
ClinicalTrials.gov Identifier: NCT03058939     History of Changes
Other Study ID Numbers: IRB15-1005
First Posted: February 23, 2017    Key Record Dates
Last Update Posted: September 3, 2018
Last Verified: August 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes

Keywords provided by University of Chicago:
Breast Cancer
Breast Cancer Stage II
Breast Cancer Stage III
Paclitaxel
Taxol

Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Paclitaxel
Albumin-Bound Paclitaxel
Carboplatin
Trastuzumab
Letrozole
Tamoxifen
Pertuzumab
Hormones
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Immunological
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Estrogen Antagonists
Hormone Antagonists
Antineoplastic Agents, Hormonal
Selective Estrogen Receptor Modulators
Estrogen Receptor Modulators